Nifty
:
23907.25
Sensex
:
79117.11
557.35 (2.39%)
1961.32 (2.54%)
Nifty
Sensex
:
:
23907.25
79117.11
557.35 (2.39%)
1961.32 (2.54%)

Zydus Lifesciences Ltd.

Pharmaceuticals & Drugs - Global

Rating :
N/A

BSE: 532321 | NSE: ZYDUSLIFE

NSE BSE
1162.45
05-Jul-2024
  • Open
  • High
  • Low
  • Previous Close
  •  1145.00
  •  1166.85
  •  1137.05
  •  1137.05
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2734011
  •  31633.53
  •  1324.30
  •  628.10

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 95,461.42
  • 22.11
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 94,017.82
  • 0.32%
  • 4.36

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 74.98%
  • 0.64%
  • 5.48%
  • FII
  • DII
  • Others
  • 7.52%
  • 10.47%
  • 0.91%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.49
  • 6.52
  • 8.96

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.69
  • 13.77
  • 10.79

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.47
  • 26.50
  • 19.20

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 24.75
  • 25.10
  • 23.42

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.03
  • 3.57
  • 3.45

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.77
  • 15.11
  • 14.62

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Net Sales
5,237.00
4,368.80
19.87%
6,207.50
5,139.60
20.78%
5,533.80
5,010.60
10.44%
4,505.20
4,257.10
5.83%
Expenses
3,821.00
3,304.90
15.62%
4,123.50
3,634.30
13.46%
3,908.60
3,755.00
4.09%
3,423.40
3,406.30
0.50%
EBITDA
1,416.00
1,063.90
33.10%
2,084.00
1,505.30
38.44%
1,625.20
1,255.60
29.44%
1,081.80
850.80
27.15%
EBIDTM
27.04%
24.35%
33.57%
29.29%
29.37%
25.06%
24.01%
19.99%
Other Income
113.60
136.20
-16.59%
63.20
36.00
75.56%
161.70
37.80
327.78%
58.30
143.70
-59.43%
Interest
25.10
8.70
188.51%
32.20
18.10
77.90%
34.60
27.70
24.91%
19.80
32.80
-39.63%
Depreciation
233.60
184.20
26.82%
215.30
179.80
19.74%
205.30
178.60
14.95%
194.80
181.60
7.27%
PBT
1,270.90
1,007.20
26.18%
1,899.70
1,329.20
42.92%
1,547.00
485.80
218.44%
925.50
780.10
18.64%
Tax
373.10
226.40
64.80%
436.10
216.10
101.80%
321.20
137.20
134.11%
213.80
195.20
9.53%
PAT
897.80
780.80
14.98%
1,463.60
1,113.10
31.49%
1,225.80
348.60
251.64%
711.70
584.90
21.68%
PATM
17.14%
17.87%
23.58%
21.66%
22.15%
6.96%
15.80%
13.74%
EPS
9.06
7.91
14.54%
14.11
10.74
31.38%
11.75
2.93
301.02%
7.80
6.16
26.62%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
21,483.50
19,547.40
17,237.40
15,109.90
14,403.50
14,253.10
13,165.60
11,954.50
9,376.50
9,426.80
8,651.30
Net Sales Growth
14.42%
13.40%
14.08%
4.90%
1.06%
8.26%
10.13%
27.49%
-0.53%
8.96%
 
Cost Of Goods Sold
6,137.50
5,260.10
5,335.70
4,757.00
4,094.20
4,243.30
4,141.30
3,656.90
3,065.00
2,673.20
2,814.10
Gross Profit
15,346.00
14,287.30
11,901.70
10,352.90
10,309.30
10,009.80
9,024.30
8,297.60
6,311.50
6,753.60
5,837.20
GP Margin
71.43%
73.09%
69.05%
68.52%
71.57%
70.23%
68.54%
69.41%
67.31%
71.64%
67.47%
Total Expenditure
15,276.50
14,248.40
13,665.50
11,935.20
11,018.20
11,472.90
10,187.20
9,125.90
7,475.00
7,097.30
6,897.40
Power & Fuel Cost
-
366.30
343.50
299.30
231.60
252.90
231.60
211.40
174.50
155.40
145.40
% Of Sales
-
1.87%
1.99%
1.98%
1.61%
1.77%
1.76%
1.77%
1.86%
1.65%
1.68%
Employee Cost
-
2,789.00
2,456.40
2,177.70
2,069.50
2,169.80
1,903.20
1,644.70
1,485.20
1,119.00
1,096.50
% Of Sales
-
14.27%
14.25%
14.41%
14.37%
15.22%
14.46%
13.76%
15.84%
11.87%
12.67%
Manufacturing Exp.
-
2,758.10
2,639.80
2,272.30
2,271.40
2,230.00
1,923.20
1,680.40
955.30
1,397.60
1,136.90
% Of Sales
-
14.11%
15.31%
15.04%
15.77%
15.65%
14.61%
14.06%
10.19%
14.83%
13.14%
General & Admin Exp.
-
625.00
620.30
506.70
444.00
582.60
583.40
398.70
466.00
356.40
326.80
% Of Sales
-
3.20%
3.60%
3.35%
3.08%
4.09%
4.43%
3.34%
4.97%
3.78%
3.78%
Selling & Distn. Exp.
-
1,800.10
1,674.60
1,373.30
1,358.60
1,468.40
1,033.30
1,129.40
826.40
979.60
1,047.20
% Of Sales
-
9.21%
9.71%
9.09%
9.43%
10.30%
7.85%
9.45%
8.81%
10.39%
12.10%
Miscellaneous Exp.
-
649.80
595.20
548.90
548.90
525.90
371.20
404.40
502.60
416.10
1,047.20
% Of Sales
-
3.32%
3.45%
3.63%
3.81%
3.69%
2.82%
3.38%
5.36%
4.41%
3.82%
EBITDA
6,207.00
5,299.00
3,571.90
3,174.70
3,385.30
2,780.20
2,978.40
2,828.60
1,901.50
2,329.50
1,753.90
EBITDA Margin
28.89%
27.11%
20.72%
21.01%
23.50%
19.51%
22.62%
23.66%
20.28%
24.71%
20.27%
Other Income
396.80
369.40
474.60
390.70
47.40
117.10
208.50
133.00
147.10
116.60
57.20
Interest
111.70
81.20
129.90
127.00
158.80
341.80
195.80
110.80
63.10
52.80
67.90
Depreciation
849.00
764.10
722.70
713.00
669.60
696.50
598.60
538.80
373.30
292.10
287.30
PBT
5,643.10
4,823.10
3,193.90
2,725.40
2,604.30
1,859.00
2,392.50
2,312.00
1,612.20
2,101.20
1,455.90
Tax
1,344.20
977.50
587.80
511.70
193.60
319.80
530.30
564.40
128.90
177.40
259.40
Tax Rate
23.82%
20.33%
22.70%
18.03%
8.07%
21.39%
22.26%
24.41%
8.00%
8.45%
17.95%
PAT
4,298.90
3,718.10
1,870.30
2,195.40
2,154.20
1,147.80
1,801.90
1,713.00
1,453.90
1,890.90
1,148.50
PAT before Minority Interest
4,163.20
3,831.40
2,001.90
2,326.40
2,205.60
1,175.60
1,851.80
1,747.60
1,483.00
1,921.30
1,186.10
Minority Interest
-135.70
-113.30
-131.60
-131.00
-51.40
-27.80
-49.90
-34.60
-29.10
-30.40
-37.60
PAT Margin
20.01%
19.02%
10.85%
14.53%
14.96%
8.05%
13.69%
14.33%
15.51%
20.06%
13.28%
PAT Growth
52.04%
98.80%
-14.81%
1.91%
87.68%
-36.30%
5.19%
17.82%
-23.11%
64.64%
 
EPS
42.72
36.95
18.59
21.82
21.41
11.41
17.91
17.02
14.45
18.79
11.41

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
19,829.50
17,515.80
16,999.60
12,992.30
10,375.70
10,386.30
8,744.50
6,960.00
5,699.20
4,251.60
Share Capital
100.60
101.20
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
Total Reserves
19,728.90
17,414.60
16,897.20
12,889.90
10,273.30
10,283.90
8,642.10
6,857.60
5,596.80
4,149.20
Non-Current Liabilities
193.10
-725.00
-193.60
19.40
2,853.90
3,491.10
2,122.20
1,903.30
736.10
1,341.50
Secured Loans
0.00
0.00
0.00
0.00
1,953.60
2,332.80
200.60
319.60
393.80
664.00
Unsecured Loans
0.00
0.00
362.10
609.50
1,261.00
1,616.90
2,354.50
2,148.80
502.60
486.40
Long Term Provisions
309.70
271.80
325.00
309.50
235.20
184.10
155.90
151.20
120.70
90.40
Current Liabilities
5,339.70
5,526.70
7,826.80
7,861.30
8,269.40
7,342.50
6,083.00
5,305.80
3,461.00
3,285.10
Trade Payables
2,126.70
2,125.00
2,137.80
2,205.90
2,044.30
1,922.60
1,888.40
1,547.90
1,308.10
1,090.90
Other Current Liabilities
1,677.60
1,798.50
1,967.50
2,166.20
2,126.30
2,033.60
1,484.90
1,212.10
860.70
628.20
Short Term Borrowings
768.60
1,081.00
3,314.10
3,070.90
3,826.50
3,196.90
2,557.50
2,476.90
1,210.90
1,183.50
Short Term Provisions
766.80
522.20
407.40
418.30
272.30
189.40
152.20
68.90
81.30
382.50
Total Liabilities
27,634.40
24,490.00
26,687.00
22,810.30
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
Net Block
12,368.50
11,520.90
12,188.50
12,132.80
12,230.50
12,163.70
6,482.60
5,755.10
3,747.90
3,352.20
Gross Block
19,919.80
18,343.80
17,650.90
17,345.00
16,781.50
15,702.30
9,349.10
8,102.90
5,767.30
5,138.50
Accumulated Depreciation
7,551.30
6,822.90
5,462.40
5,212.20
4,551.00
3,538.60
2,866.50
2,345.80
2,016.80
1,786.30
Non Current Assets
16,135.20
14,477.60
14,438.20
14,094.30
14,118.30
14,014.70
8,911.00
8,302.90
5,751.70
4,820.40
Capital Work in Progress
2,423.30
1,200.70
725.90
783.20
741.50
837.20
1,527.20
1,543.30
950.80
797.90
Non Current Investment
968.00
927.30
934.80
631.20
552.20
443.60
470.90
385.70
217.10
33.20
Long Term Loans & Adv.
344.50
358.70
369.30
323.30
332.00
410.40
300.00
384.70
661.20
637.10
Other Non Current Assets
30.90
470.00
219.70
223.80
262.10
159.80
130.30
234.10
174.70
0.00
Current Assets
11,419.80
10,008.20
12,095.20
8,716.00
8,715.40
8,498.10
8,229.70
6,022.30
4,280.40
4,226.70
Current Investments
252.50
619.30
2,353.20
198.90
212.80
229.90
274.80
49.10
199.10
121.20
Inventories
3,441.90
3,413.30
3,719.40
3,236.20
2,789.00
2,688.00
2,385.30
1,803.70
1,337.10
1,535.70
Sundry Debtors
5,220.20
4,416.80
3,340.30
3,127.30
3,663.20
3,950.80
3,206.30
2,277.50
1,746.60
1,588.40
Cash & Bank
1,105.10
573.10
1,106.90
888.30
964.90
548.90
1,314.90
1,543.50
638.70
669.90
Other Current Assets
1,400.10
274.00
229.90
523.90
1,085.50
1,080.50
1,048.40
348.50
358.90
311.50
Short Term Loans & Adv.
735.90
711.70
1,345.50
741.40
643.90
584.50
527.70
268.50
234.80
240.80
Net Current Assets
6,080.10
4,481.50
4,268.40
854.70
446.00
1,155.60
2,146.70
716.50
819.40
941.60
Total Assets
27,555.00
24,485.80
26,533.40
22,810.30
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
3,227.90
2,688.80
2,104.50
3,293.90
2,931.50
1,281.90
919.30
1,311.70
1,893.50
993.60
PBT
4,838.10
2,582.70
5,232.30
2,284.80
1,495.40
2,382.10
2,312.00
1,611.90
2,098.70
1,445.50
Adjustment
546.70
933.90
-2,117.20
1,163.00
1,474.40
539.10
624.30
333.70
249.80
344.50
Changes in Working Capital
-871.10
-235.80
-336.00
191.10
263.80
-971.70
-1,383.90
-411.20
271.70
-377.00
Cash after chg. in Working capital
4,513.70
3,280.80
2,779.10
3,638.90
3,233.60
1,949.50
1,552.40
1,534.40
2,620.20
1,413.00
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,285.80
-592.00
-674.60
-345.00
-302.50
-675.40
-602.30
-237.60
-646.00
-386.90
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.40
7.80
-30.80
14.90
-80.70
-32.50
Cash From Investing Activity
-1,475.20
1,535.00
-1,000.30
-724.60
-1,012.30
-4,238.70
-973.70
-2,871.90
-863.50
-464.70
Net Fixed Assets
-572.20
-669.30
-490.20
-462.80
-289.60
-1,652.30
-600.20
-557.40
-531.50
-271.50
Net Investments
-2,403.70
238.70
1,352.60
-66.50
-2,208.90
-577.10
305.60
-1,606.20
-108.40
-651.40
Others
1,500.70
1,965.60
-1,862.70
-195.30
1,486.20
-2,009.30
-679.10
-708.30
-223.60
458.20
Cash from Financing Activity
-1,810.40
-4,400.40
-868.30
-2,547.70
-1,528.20
1,884.60
51.50
2,315.80
-934.80
-351.10
Net Cash Inflow / Outflow
-57.70
-176.60
235.90
21.60
391.00
-1,072.20
-2.90
755.60
95.20
177.80
Opening Cash & Equivalents
487.80
657.80
888.30
1,177.70
778.80
1,589.70
1,592.60
837.00
737.90
612.60
Closing Cash & Equivalent
413.00
487.80
1,106.90
1,087.20
1,177.70
778.80
1,589.70
1,592.60
837.00
790.40

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
197.11
173.08
166.01
126.88
101.33
101.43
85.40
67.97
55.66
41.52
ROA
14.70%
7.82%
9.40%
9.66%
5.18%
9.34%
11.11%
12.18%
20.14%
13.93%
ROE
20.52%
11.60%
15.51%
18.88%
11.32%
19.36%
22.26%
23.43%
38.62%
30.85%
ROCE
24.90%
13.64%
15.30%
14.23%
10.02%
15.89%
18.41%
16.50%
28.60%
23.21%
Fixed Asset Turnover
1.98
1.88
1.69
1.69
0.88
1.05
1.38
1.38
1.76
1.80
Receivable days
46.37
41.75
39.94
42.92
97.49
99.21
83.37
76.72
63.29
56.38
Inventory Days
32.98
38.39
42.95
38.08
70.13
70.33
63.69
59.88
54.52
60.13
Payable days
147.51
145.80
166.64
189.45
64.85
68.81
68.11
74.18
65.30
55.05
Cash Conversion Cycle
-68.16
-65.67
-83.76
-108.45
102.77
100.73
78.94
62.42
52.51
61.46
Total Debt/Equity
0.04
0.07
0.25
0.35
0.77
0.76
0.62
0.75
0.43
0.62
Interest Cover
60.22
20.94
23.35
16.11
5.38
13.17
21.87
26.55
40.75
22.29

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Zydus Lifesciences gets in principle acceptability from WHO for ZyVac TCV
    23rd Oct 2024, 11:20 AM

    ZyVac TCV is indigenously developed and manufactured at the Zydus Biotech Park, Ahmedabad

    Read More
  • Zydus Lifesciences gets USFDA’s approval for Fludrocortisone Acetate Tablets
    18th Oct 2024, 09:39 AM

    Fludrocortisone acetate tablets will be produced at the Group’s manufacturing site at Moraiya, Ahmedabad

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Paliperidone Extended-Release Tablets
    10th Oct 2024, 14:57 PM

    Paliperidone extended-release tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad

    Read More
  • Zydus Lifesciences gets USFDA’s tentative approval for Enzalutamide Tablets
    3rd Oct 2024, 10:51 AM

    Enzalutamide Tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad

    Read More
  • Zydus Lifesciences gets EIR for transdermal manufacturing facility
    1st Oct 2024, 14:07 PM

    This facility underwent an inspection from July 15 to 19, 2024

    Read More
  • Zydus Lifesciences gets nod to manufacture Enzalutamide Capsules
    30th Sep 2024, 09:50 AM

    Enzalutamide capsules, 40 mg had annual sales of $869.4 million in the United States

    Read More
  • Zydus Lifesciences, CSIR- CDRI to develop drug for chronic kidney disease induced Osteoporosis
    27th Sep 2024, 11:00 AM

    Any drug candidate emerging from the efforts will be developed by Zydus for India and other markets

    Read More
  • Zydus Lifesciences to purchase API business of Sterling Biotech
    17th Sep 2024, 15:27 PM

    The Target Business of SBL consists of a portfolio of fermentation-based API products like Lovastatin, Daunorubicin, Doxorubicin and Epirubicin

    Read More
  • Zydus Lifesciences gets warning letter from USFDA for Jarod facility
    30th Aug 2024, 17:26 PM

    The Warning Letter does not contain any data integrity related violations

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Scopolamine Transdermal System
    30th Aug 2024, 12:59 PM

    The Scopolamine Transdermal System will be produced at the group’s transdermal manufacturing site at SEZ, Matoda, Ahmedabad

    Read More
  • Zydus Lifesciences gets final nod to market Amantadine extended-release capsules
    28th Aug 2024, 09:23 AM

    The company has also received tentative approval for 137 mg (USRLD: Gocovri (amantadine) extended-release capsules, 68.5 mg and 137 mg)

    Read More
  • Zydus Lifesciences to acquire 50% stake in Sterling Biotech from Perfect Day
    24th Aug 2024, 10:52 AM

    Post this transaction, Sterling Biotech will become a 50:50 Joint Venture with equal representation on the Board

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.